你知道A股历史上发行价最高的股票，现在都怎么样了吗？ 答案可能让你倒吸一口凉气。 十只曾经风光无限的"贵族股"，经过市场几年的洗礼，竟然有七 只已经跌破了发行价。 更让人震惊的是，其中一只从历史最高点下跌了整整93%，几乎跌没了。 这些股票大多集中在科创板和创业板，发行价动辄两三百 元，甚至超过五百元，上市时都是万众瞩目的明星。 如今，它们的走势却集体上演了一出"高台跳水"。 这十只股票包括禾迈股份、万润新能、义翘神州、石头科技、索辰科技、福昕软件、华宝新能、纳芯微、康希诺和百济神州。 它们上市的时间分布在2020年到2023年之间，正是注册制改革推进、新股发行活跃的时期。 高发行价背后，是当时市场对硬科技、新能源、生物医药等赛道火热的追捧。 然而，潮水退去后，谁在裸泳一目了然。 先来看看整体情况。 截至2026年2月中旬，这十只股票中，只有石头科技、纳芯微和百济神州三只的股价还在发行价之上。 但需要注意的是，这三只股票在上市后的历程中也曾一度跌破发行价，只是借助近一年的市场行情才勉强拉了回来。 其余七只股票，则全部处于破发状态，意味着所有在发行时买入并持有至今的投资者，账面上都是亏损的。 破发的幅度各不相同 ...

Group 1 - The core viewpoint of the news is that Yiqiao Shenzhou (301047) is participating in the 15th Cell Biology Industry Conference, which focuses on cell therapy and regenerative medicine, scheduled for March 5-6, 2026, in Chengdu [1] - The number of shareholders in Yiqiao Shenzhou increased by 2.44% as of February 9, 2026, indicating a change in investor interest [1] Group 2 - Over the past 7 days (February 6 to 11, 2026), Yiqiao Shenzhou's stock price fluctuated within a range of 0.34%, with a high of 74.77 yuan and a low of 73.14 yuan, showing a volatile trend [2] - On February 11, 2026, there was a net outflow of 1.1075 million yuan in main funds, while retail investor activity remained high [2] Group 3 - As of February 12, 2026, institutions set a comprehensive target price for Yiqiao Shenzhou at 78.00 yuan, indicating limited upside potential compared to the latest stock price [3] - The forecast for net profit in 2025 is expected to grow by 18.10%, while revenue for 2026 is projected to increase by 9.06% [3] - Market sentiment is neutral, and the frequency of institutional research is relatively low [3]

（文章来源：证券日报） 证券日报网讯 2月9日，义翘神州在互动平台回答投资者提问时表示，根据中国证券登记结算有限责任 公司提供数据（未合并融资融券信用账户），2026年1月30日股东人数为20081户。 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Core Viewpoint - Yiqiao Shenzhou's stock price experienced a slight decline of 0.17% on January 29, with a trading volume of 97.49 million yuan, indicating a mixed market sentiment towards the company [1]. Financing Summary - On January 29, Yiqiao Shenzhou had a financing buy-in amount of 8.13 million yuan and a financing repayment of 11.76 million yuan, resulting in a net financing outflow of 3.64 million yuan [1]. - The total financing and securities balance for Yiqiao Shenzhou reached 258 million yuan, with the financing balance accounting for 2.80% of the circulating market value, which is above the 60th percentile of the past year [1]. - The company had a low short-selling balance of 709,800 yuan, indicating a lower level of short-selling activity compared to the past year [1]. Business Performance - As of January 9, Yiqiao Shenzhou had 19,600 shareholders, reflecting a 1.43% increase, while the average circulating shares per person decreased by 1.41% to 6,100 shares [2]. - For the period from January to September 2025, Yiqiao Shenzhou reported a revenue of 511 million yuan, representing a year-on-year growth of 10.00%, and a net profit attributable to shareholders of 110 million yuan, with a growth of 10.94% [2]. Dividend Information - Since its A-share listing, Yiqiao Shenzhou has distributed a total of 1.802 billion yuan in dividends, with 1.122 billion yuan distributed over the past three years [3]. - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, increasing its holdings by 200,200 shares to 919,600 shares [3].

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Group 1 - The company Yiqiao Shenzhou stated that as of December 31, 2025, the number of shareholders is expected to reach 19,326 households [2]

证券日报网讯1月13日，义翘神州（301047）在互动平台回答投资者提问时表示，根据中国证券登记结 算有限责任公司提供数据(未合并融资融券信用账户)，2026年1月9日股东人数为19，603户。 ...

从资金流向上来看，当日生物制品板块主力资金净流入3.99亿元，游资资金净流出6286.66万元，散户资 金净流出3.36亿元。生物制品板块个股资金流向见下表： 证券之星消息，1月13日生物制品板块较上一交易日上涨1.15%，康乐卫士领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920575 | 康乐卫士 | 11.99 | 29.90% | 35.12万 | | 4.02亿 | | 688331 | 荣昌生物 | 114.46 | 20.00% | 21.22万 | | 23.69亿 | | 688137 | 沂岸蛋白 | 49.60 | 15.43% | 5.81万 | | 2.91亿 | | 920344 | 三元基因 | 28.45 | 11.44% | 6.86万 | | 1.94亿 | | 301047 | 义翘神州 | 82.02 | ...

近日，北京义翘神州科技股份有限公司(以下简称：义翘神州)获得Scientist.com平台颁发的"2025年度供 应商绩效认可奖"(2025 Supplier Performance Recognition Award)，旨在表彰义翘神州在推动全球药物发 现研究方面做出的杰出贡献和卓越表现。 义翘神州通过哺乳动物细胞、杆状病毒-昆虫细胞、大肠杆菌及无细胞表达(CFPS)四大系统，为您提供 从基因合成到蛋白表达、纯化的一站式服务，是您定制重组蛋白表达的理想合作伙伴。义翘神州构建的 杂交瘤、Beacon®、流式单B、噬菌体和兔多抗技术五大抗体发现平台，成功开发30000+抗体，与很多 国际制药企业建立了良好的合作关系。 义翘神州美国公司首席商务官Rob Burgess表示： "我们深感荣幸能够获得Scientist.com的认可与肯定。也为双方长期而富有成效的合作深感自豪。这一奖 项充分彰显了我们团队致力于为全球科学界提供可靠、及时、创新解决方案的坚定承诺。未来，我们将 继续致力于赋能科研人员，为生命科学研究的进步贡献更大力量。" Scientist.com是全球大型的智能化生命科学研发采购平台，整合6000多家 ...